Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

reated patients. The primary endpoint was ORR and secondary endpoints included CBR, TTP, DOR, OS and safety.
  • The 003-A1 study was an open-label, single-arm Phase 2b trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies, including bortezomib and either thalidomide or lenalidomide. Refractory disease was defined as less than or equal to a 25 percent response or progression during therapy, or progression within 60 days after completion of therapy.[ii]  The primary endpoint was ORR. Secondary endpoints included DOR, CBR, OS, TTP, PFS, and safety. 
  • The 007 study is an open-label Phase 1b/2 study. Results were reported from the dose-expansion phase of this ongoing study, which evaluated the safety and efficacy of a prolonged, 30-minute infusion of carfilzomib at a dose of 56mg/m(2). Endpoints included ORR, DOR, PFS, TTP, pharmacokinetics and safety.
  •  

    ASH Investor Teleconference
    Investigators and members of the Onyx management team will highlight data presented on carfilzomib featured at the 53rd ASH Annual Meeting and Exposition in San Diego, CA. The teleconference will begin at 10:00 a.m. PT on December 13, 2011.

    Interested parties may access the teleconference and the presentation that accompanies it on our website at:  

    http://www.onyx-pharm.com/investors/event-calendar

    or by dialing 847-585-4405 and using the passcode 31296220.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 31296220# later in the day.  The replay will be available on the Onyx website until December 27, 2011.

    Carfilzomib Development Program
    Carfilzomib is being studied in several clinical trials either as a single-agent or in combi
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
    (Date:5/22/2015)... The North American dental lasers market ... to reach $90.7 million by 2019, at a CAGR of ... TOC of North America Dental Lasers Market for an analysis ... tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ...   Dental lasers are specifically used in ...
    (Date:5/22/2015)... YORK , May 22, 2015  The ... of Zarxio (filgrastim-sndz) -- the first biosimilar product ... -- points toward growth in the contract ... The mainstream CMO industry is geared to the ... to produce major biopharmaceutical products. The healthcare market ...
    Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
    ... 16, 2011 ZONARE Medical Systems today announced ... Sullivan 2011 North American Technology Innovation Award in ... development of Zone Sonography Technology (ZST), the Frost ... of the industry,s most significant ultrasound breakthroughs. ...
    ... Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ... it has entered into a collaborative research agreement with ... Phase II clinical trials treating melanoma, Merkel cell ... identifying biomarkers that may refine and enhance the selection ...
    Cached Medicine Technology:Frost & Sullivan Honors ZONARE for Ultrasound Innovation 2OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies 2OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies 3OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies 4
    (Date:5/22/2015)... 22, 2015 Pioneer Millworks, the largest ... forefront of designing with reclaimed wood, introducing their latest ... Angeles, California. Their newest offerings, Vat 35, Reclaimed ... and color to America's largest design event. , “Designers, ... each show, anxious to see and feel the variety ...
    (Date:5/22/2015)... (PRWEB) May 22, 2015 River Valley ... Kyle Johnson, the health system’s Chief Financial Officer (CFO), ... Johnson has served as the company CFO since 2011. ... will be joining the health system as CFO. Wesley ... interim basis, while the Board of Trustees conducts a ...
    (Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton ... 2015 Congress of Future Medical Leaders in Boston, Mass. ... “America’s highest achieving high school students.” , “I’m excited ... goals and learn better study habits,” said Omar. “The ... we can ask the surgeons questions.” , The goal ...
    (Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
    (Date:5/22/2015)... 22, 2015 Coordinating care for ... process. Historically providers have not been reimbursed or ... in 2015, Medicare has paved the way by ... to the launch of Oculus Health , ... systems using the platform will now be able ...
    Breaking Medicine News(10 mins):Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4
    ... By Alan Mozes HealthDay Reporter , THURSDAY, ... illness are being reported among college students than a decade ... a post-secondary education and are open to getting help when ... use of prescription medications by students to treat psychiatric illness ...
    ... European Urology , the official journal of the European Association ... the September issue: Case Series of the month. This series ... only preliminary results. The Case Series reports on no more ... Education question with multiple choice answers is also included to ...
    ... , WEDNESDAY, Aug. 11 (HealthDay News) -- A debilitating and usually ... transplant, a new study finds. , , The results may ... for the potential of stem cells in bone marrow to turn ... Aug. 12 issue of the New England Journal of Medicine ...
    ... nationwide research initiative has been launched to define changes in ... in response to infection or to vaccination. Six U. S.-based ... million over five years to conduct this research. ... of Allergy and Infectious Diseases (NIAID), part of the National ...
    ... least a quarter of patients who have suffered a stroke ... medications within the first three months after being hospitalized ... according to a new study by researchers at Wake Forest ... there are an estimated 180,000 recurrent strokes in the United ...
    ... Medicine,s Department of Public Health Sciences has received a ... act as the data coordinating center for the National ... one of the largest in the college,s history. AsthmaNet ... the nation that conducts clinical trials to address new ...
    Cached Medicine News:Health News:College Campuses See Rise in Cases of Severe Mental Illness 2Health News:College Campuses See Rise in Cases of Severe Mental Illness 3Health News:New case series section in European Urology 2Health News:Stem Cell Treatment May Offer Hope Against Fatal Skin Disorder 2Health News:Stem Cell Treatment May Offer Hope Against Fatal Skin Disorder 3Health News:NIH launches effort to define markers of human immune responses 2Health News:1 in 4 stroke patients stop taking prevention medication within 3 months 2Health News:1 in 4 stroke patients stop taking prevention medication within 3 months 3Health News:1 in 4 stroke patients stop taking prevention medication within 3 months 4Health News:College Of Medicine receives $54 million grant for asthma research 2
    Each handle is designed to fit a specific trephine size....
    Each handle is designed to fit a specific trephine size....
    Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
    Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
    Medicine Products: